CSPC PHARMA's Duoniyi Xin for new indications has been approved for marketing

AASTOCKS
2025.12.14 08:24

CSPC PHARMA (01093.HK) announced that the new indication for the liposomal injection of Irinotecan Hydrochloride (trade name: Doreniy) developed by the group has been approved for marketing by the National Medical Products Administration of China. The newly approved indication is for first-line treatment in patients with metastatic pancreatic cancer in combination with Oxaliplatin, 5-Fluorouracil, and Leucovorin, marking the second indication approved for this product in China

Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.